Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 23, 2008. The report details a specific corporate action regarding a share repurchase executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to a share buyback.
- Shares Repurchased: 3,000,000 Ordinary shares of 25 pence each.
- Repurchase Price: 1,212.8803 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.05% of total voting rights).
- Shares in Issue: 5,240,433,283 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's share capital through the cancellation of 3,000,000 repurchased shares. Consequently, the number of shares held in Treasury increased to 474,194,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance disclosure confirming the execution of a share buyback and the resulting capital structure, conforming to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cost of the repurchase (3,000,000 shares at 1,212.8803 pence).
- Confirm the updated total voting rights denominator (5,240,433,283 shares) for regulatory disclosure thresholds.
- Review the impact of the 9.05% Treasury share holding on future earnings per share calculations.
- Check subsequent filings for the remaining authorized share buyback capacity.